Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Respuestas clínicas Cochrane

Topics

Temas

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 1 The composite vascular death, non‐fatal stroke, non‐fatal myocardial infarction or major bleeding complication.
Figuras y tablas -
Analysis 1.1

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 1 The composite vascular death, non‐fatal stroke, non‐fatal myocardial infarction or major bleeding complication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 2 All death.
Figuras y tablas -
Analysis 1.2

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 2 All death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 3 Vascular death.
Figuras y tablas -
Analysis 1.3

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 3 Vascular death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 4 Vascular death or non‐fatal stroke.
Figuras y tablas -
Analysis 1.4

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 4 Vascular death or non‐fatal stroke.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 5 Vascular death, non‐fatal stroke or non‐fatal myocardial infarction.
Figuras y tablas -
Analysis 1.5

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 5 Vascular death, non‐fatal stroke or non‐fatal myocardial infarction.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 6 Recurrent ischaemic stroke.
Figuras y tablas -
Analysis 1.6

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 6 Recurrent ischaemic stroke.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 7 Recurrent ischaemic stroke or intracranial haemorrhage.
Figuras y tablas -
Analysis 1.7

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 7 Recurrent ischaemic stroke or intracranial haemorrhage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 8 Death or dependent at end of follow‐up.
Figuras y tablas -
Analysis 1.8

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 8 Death or dependent at end of follow‐up.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 9 Major bleeding complication.
Figuras y tablas -
Analysis 1.9

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 9 Major bleeding complication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 10 Fatal intracranial or extracranial haemorrhage.
Figuras y tablas -
Analysis 1.10

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 10 Fatal intracranial or extracranial haemorrhage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 11 Intracranial haemorrhage, fatal or non‐fatal.
Figuras y tablas -
Analysis 1.11

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 11 Intracranial haemorrhage, fatal or non‐fatal.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 12 Major extracranial haemorrhage.
Figuras y tablas -
Analysis 1.12

Comparison 1 Vitamin K antagonists versus antiplatelet therapy, Outcome 12 Major extracranial haemorrhage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 1 The composite vascular death, non‐fatal stroke, non‐fatal myocardial infarction or major bleeding complication.
Figuras y tablas -
Analysis 2.1

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 1 The composite vascular death, non‐fatal stroke, non‐fatal myocardial infarction or major bleeding complication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 2 All death.
Figuras y tablas -
Analysis 2.2

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 2 All death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 3 Vascular death.
Figuras y tablas -
Analysis 2.3

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 3 Vascular death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 4 Vascular death or non‐fatal stroke.
Figuras y tablas -
Analysis 2.4

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 4 Vascular death or non‐fatal stroke.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 5 Vascular death, non‐fatal stroke or non‐fatal myocardial infarction.
Figuras y tablas -
Analysis 2.5

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 5 Vascular death, non‐fatal stroke or non‐fatal myocardial infarction.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 6 Recurrent ischaemic stroke.
Figuras y tablas -
Analysis 2.6

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 6 Recurrent ischaemic stroke.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 7 Recurrent ischaemic stroke or intracranial haemorrhage.
Figuras y tablas -
Analysis 2.7

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 7 Recurrent ischaemic stroke or intracranial haemorrhage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 8 Death or dependent at end of follow‐up.
Figuras y tablas -
Analysis 2.8

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 8 Death or dependent at end of follow‐up.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 9 Major bleeding complication.
Figuras y tablas -
Analysis 2.9

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 9 Major bleeding complication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 10 Fatal intracranial or extracranial haemorrhage.
Figuras y tablas -
Analysis 2.10

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 10 Fatal intracranial or extracranial haemorrhage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 11 Intracranial haemorrhage, fatal or non‐fatal.
Figuras y tablas -
Analysis 2.11

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 11 Intracranial haemorrhage, fatal or non‐fatal.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 12 Major extracranial haemorrhage.
Figuras y tablas -
Analysis 2.12

Comparison 2 Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials), Outcome 12 Major extracranial haemorrhage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 1 The composite vascular death, non‐fatal stroke, non‐fatal myocardial infarction or major bleeding complication.
Figuras y tablas -
Analysis 3.1

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 1 The composite vascular death, non‐fatal stroke, non‐fatal myocardial infarction or major bleeding complication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 2 All death.
Figuras y tablas -
Analysis 3.2

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 2 All death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 3 Vascular death.
Figuras y tablas -
Analysis 3.3

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 3 Vascular death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 4 Vascular death or non‐fatal stroke.
Figuras y tablas -
Analysis 3.4

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 4 Vascular death or non‐fatal stroke.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 5 Vascular death, non‐fatal stroke or non‐fatal myocardial infarction.
Figuras y tablas -
Analysis 3.5

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 5 Vascular death, non‐fatal stroke or non‐fatal myocardial infarction.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 6 Recurrent ischaemic stroke.
Figuras y tablas -
Analysis 3.6

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 6 Recurrent ischaemic stroke.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 7 Recurrent ischaemic stroke or intracranial haemorrhage.
Figuras y tablas -
Analysis 3.7

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 7 Recurrent ischaemic stroke or intracranial haemorrhage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 8 Death or dependent at end of follow‐up.
Figuras y tablas -
Analysis 3.8

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 8 Death or dependent at end of follow‐up.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 9 Major bleeding complication.
Figuras y tablas -
Analysis 3.9

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 9 Major bleeding complication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 10 Fatal intracranial or extracranial haemorrhage.
Figuras y tablas -
Analysis 3.10

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 10 Fatal intracranial or extracranial haemorrhage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 11 Intracranial haemorrhage, fatal or non‐fatal.
Figuras y tablas -
Analysis 3.11

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 11 Intracranial haemorrhage, fatal or non‐fatal.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 12 Major extracranial haemorrhage.
Figuras y tablas -
Analysis 3.12

Comparison 3 Vitamin K antagonists versus aspirin only, Outcome 12 Major extracranial haemorrhage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 1 The composite vascular death, non‐fatal stroke, non‐fatal myocardial infarction or major bleeding complication.
Figuras y tablas -
Analysis 4.1

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 1 The composite vascular death, non‐fatal stroke, non‐fatal myocardial infarction or major bleeding complication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 2 All death.
Figuras y tablas -
Analysis 4.2

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 2 All death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 3 Vascular death.
Figuras y tablas -
Analysis 4.3

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 3 Vascular death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 4 Vascular death or non‐fatal stroke.
Figuras y tablas -
Analysis 4.4

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 4 Vascular death or non‐fatal stroke.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 5 Vascular death, non‐fatal stroke or non‐fatal myocardial infarction.
Figuras y tablas -
Analysis 4.5

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 5 Vascular death, non‐fatal stroke or non‐fatal myocardial infarction.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 6 Recurrent ischaemic stroke.
Figuras y tablas -
Analysis 4.6

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 6 Recurrent ischaemic stroke.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 7 Recurrent ischaemic stroke or intracranial haemorrhage.
Figuras y tablas -
Analysis 4.7

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 7 Recurrent ischaemic stroke or intracranial haemorrhage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 8 Death or dependent at end of follow‐up.
Figuras y tablas -
Analysis 4.8

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 8 Death or dependent at end of follow‐up.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 9 Major bleeding complication.
Figuras y tablas -
Analysis 4.9

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 9 Major bleeding complication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 10 Fatal intracranial or extracranial haemorrhage.
Figuras y tablas -
Analysis 4.10

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 10 Fatal intracranial or extracranial haemorrhage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 11 Intracranial haemorrhage, fatal or non‐fatal.
Figuras y tablas -
Analysis 4.11

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 11 Intracranial haemorrhage, fatal or non‐fatal.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 12 Major extracranial haemorrhage.
Figuras y tablas -
Analysis 4.12

Comparison 4 Vitamin K antagonists versus aspirin, including intracranial artery stenosis, Outcome 12 Major extracranial haemorrhage.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. Vitamin K antagonists versus antiplatelet therapy

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 The composite vascular death, non‐fatal stroke, non‐fatal myocardial infarction or major bleeding complication Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 INR 2.0 ‐ 3.6

1

1068

Risk Ratio (M‐H, Fixed, 95% CI)

1.00 [0.78, 1.29]

1.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.30 [1.58, 3.35]

2 All death Show forest plot

6

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 INR 1.4 ‐ 2.8

1

2206

Risk Ratio (M‐H, Fixed, 95% CI)

0.89 [0.60, 1.30]

2.2 INR 2.0 ‐ 3.6

4

1561

Risk Ratio (M‐H, Fixed, 95% CI)

1.33 [0.94, 1.88]

2.3 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.38 [1.31, 4.32]

3 Vascular death Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 INR 2.0 ‐ 3.6

3

1444

Risk Ratio (M‐H, Fixed, 95% CI)

1.35 [0.84, 2.16]

3.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.23 [1.10, 4.51]

4 Vascular death or non‐fatal stroke Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 INR 2.0 ‐ 3.6

3

1444

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.71, 1.22]

4.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

1.69 [1.08, 2.65]

5 Vascular death, non‐fatal stroke or non‐fatal myocardial infarction Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 INR 2.0 ‐ 3.6

1

1068

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.65, 1.12]

5.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

1.70 [1.12, 2.59]

6 Recurrent ischaemic stroke Show forest plot

4

2760

Risk Ratio (M‐H, Fixed, 95% CI)

0.84 [0.61, 1.15]

6.1 INR 2.0 ‐ 3.6

3

1444

Risk Ratio (M‐H, Fixed, 95% CI)

0.80 [0.56, 1.14]

6.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.49, 2.13]

7 Recurrent ischaemic stroke or intracranial haemorrhage Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 INR 2.0 ‐ 3.6

4

1561

Risk Ratio (M‐H, Fixed, 95% CI)

0.91 [0.66, 1.24]

7.2 INR 3. 0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.04 [1.21, 3.46]

8 Death or dependent at end of follow‐up Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.30 [1.37, 3.85]

9 Major bleeding complication Show forest plot

6

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 INR 1.4 ‐ 2.8

1

2206

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [0.79, 2.03]

9.2 INR 2.0 ‐ 3.6

4

1561

Risk Ratio (M‐H, Fixed, 95% CI)

1.93 [1.27, 2.94]

9.3 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

9.02 [3.91, 20.84]

10 Fatal intracranial or extracranial haemorrhage Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 INR 1.4 ‐ 2.8

1

2206

Risk Ratio (M‐H, Fixed, 95% CI)

1.4 [0.45, 4.40]

10.2 INR 2.0 ‐ 3.6

3

1444

Risk Ratio (M‐H, Fixed, 95% CI)

2.18 [0.83, 5.75]

10.3 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

17.37 [2.32, 130.11]

11 Intracranial haemorrhage, fatal or non‐fatal Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 INR 2.0 ‐ 3.6

3

1444

Risk Ratio (M‐H, Fixed, 95% CI)

1.82 [0.88, 3.78]

11.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

9.19 [2.80, 30.16]

12 Major extracranial haemorrhage Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 INR 2.0 ‐ 3.6

3

1444

Risk Ratio (M‐H, Fixed, 95% CI)

2.77 [1.55, 4.96]

12.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

8.85 [2.69, 29.11]
Figuras y tablas -
Comparison 1. Vitamin K antagonists versus antiplatelet therapy
Ir a la tabla de la revisión
Comparison 2. Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 The composite vascular death, non‐fatal stroke, non‐fatal myocardial infarction or major bleeding complication Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 INR 2.0 ‐ 3.6

1

1068

Risk Ratio (M‐H, Fixed, 95% CI)

1.00 [0.78, 1.29]

1.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.30 [1.58, 3.35]

2 All death Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 INR 1.4 ‐ 2.8 concealed randomisation

1

2206

Risk Ratio (M‐H, Fixed, 95% CI)

0.89 [0.60, 1.30]

2.2 INR 2.0 ‐ 3.6 concealed randomisation

2

1185

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [0.88, 1.83]

2.3 INR 3.0 ‐ 4.5 concealed randomisation

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.38 [1.31, 4.32]

3 Vascular death Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 INR 2.0 ‐ 3.6

1

1068

Risk Ratio (M‐H, Fixed, 95% CI)

1.28 [0.76, 2.15]

3.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.23 [1.10, 4.51]

4 Vascular death or non‐fatal stroke Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 INR 2.0 ‐ 3.6

1

1068

Risk Ratio (M‐H, Fixed, 95% CI)

0.90 [0.67, 1.22]

4.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

1.69 [1.08, 2.65]

5 Vascular death, non‐fatal stroke or non‐fatal myocardial infarction Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 INR 2.0 ‐ 3.6

1

1068

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.65, 1.12]

5.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

1.70 [1.12, 2.59]

6 Recurrent ischaemic stroke Show forest plot

2

2384

Risk Ratio (M‐H, Fixed, 95% CI)

0.82 [0.58, 1.16]

6.1 INR 2.0 ‐ 3.6

1

1068

Risk Ratio (M‐H, Fixed, 95% CI)

0.77 [0.52, 1.13]

6.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.49, 2.13]

7 Recurrent ischaemic stroke or intracranial haemorrhage Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 INR 2.0 ‐ 3. 6 concealed randomisation

2

1185

Risk Ratio (M‐H, Fixed, 95% CI)

0.90 [0.64, 1.26]

7.2 INR 3.0 ‐ 4.5 concealed randomisation

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.04 [1.21, 3.46]

8 Death or dependent at end of follow‐up Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.30 [1.37, 3.85]

9 Major bleeding complication Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 INR 1.4 ‐ 2.8 concealed randomisation

1

2206

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [0.79, 2.03]

9.2 INR 2.0 ‐ 3.6 concealed randomisation

2

1185

Risk Ratio (M‐H, Fixed, 95% CI)

1.84 [1.14, 2.97]

9.3 INR 3.0 ‐ 4.5 concealed randomisation

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

9.02 [3.91, 20.84]

10 Fatal intracranial or extracranial haemorrhage Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 INR 1.4 ‐ 2.8 concealed randomisation

1

2206

Risk Ratio (M‐H, Fixed, 95% CI)

1.4 [0.45, 4.40]

10.2 INR 2.0 ‐ 3.6 concealed randomisation

1

1068

Risk Ratio (M‐H, Fixed, 95% CI)

2.73 [0.87, 8.52]

10.3 INR 3.0 ‐ 4.5 concealed randomisation

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

17.37 [2.32, 130.11]

11 Intracranial haemorrhage, fatal or non‐fatal Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 INR 2.0 ‐ 3.6

1

1068

Risk Ratio (M‐H, Fixed, 95% CI)

1.99 [0.90, 4.38]

11.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

9.19 [2.80, 30.16]

12 Major extracranial haemorrhage Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 INR 2.0 ‐ 3.6

1

1068

Risk Ratio (M‐H, Fixed, 95% CI)

2.98 [1.41, 6.27]

12.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

8.85 [2.69, 29.11]
Figuras y tablas -
Comparison 2. Vitamin K antagonists versus antiplatelet therapy (concealed randomised trials)
Ir a la tabla de la revisión
Comparison 3. Vitamin K antagonists versus aspirin only

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 The composite vascular death, non‐fatal stroke, non‐fatal myocardial infarction or major bleeding complication Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 INR 2.0 ‐ 3.6

1

1068

Risk Ratio (M‐H, Fixed, 95% CI)

1.00 [0.78, 1.29]

1.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.30 [1.58, 3.35]

2 All death Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 INR 1.4 ‐ 2.8

1

2206

Risk Ratio (M‐H, Fixed, 95% CI)

0.89 [0.60, 1.30]

2.2 INR 2.0 ‐ 3.6

3

1426

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [0.88, 1.80]

2.3 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.38 [1.31, 4.32]

3 Vascular death Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 INR 2.0 ‐ 3.6

2

1309

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [0.77, 2.07]

3.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.23 [1.10, 4.51]

4 Vascular death or non‐fatal stroke Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 INR 2.0 ‐ 3.6

2

1309

Risk Ratio (M‐H, Fixed, 95% CI)

0.91 [0.69, 1.21]

4.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

1.69 [1.08, 2.65]

5 Vascular death, non‐fatal stroke or non‐fatal myocardial infarction Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 INR 2.0 ‐ 3.6

1

1068

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.65, 1.12]

5.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

1.70 [1.12, 2.59]

6 Recurrent ischaemic stroke Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 INR 2.0 ‐ 3.6

2

1309

Risk Ratio (M‐H, Fixed, 95% CI)

0.82 [0.57, 1.18]

6.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.49, 2.13]

7 Recurrent ischaemic stroke or intracranial haemorrhage Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 INR 2.0 ‐ 3.6

3

1426

Risk Ratio (M‐H, Fixed, 95% CI)

0.92 [0.67, 1.27]

7.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.04 [1.21, 3.46]

8 Death or dependent at end of follow‐up Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.30 [1.37, 3.85]

9 Major bleeding complication Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 INR 1.4 ‐ 2.8

1

2206

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [0.79, 2.03]

9.2 INR 2.0 ‐ 3.6

3

1426

Risk Ratio (M‐H, Fixed, 95% CI)

1.89 [1.21, 2.95]

9.3 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

9.02 [3.91, 20.84]

10 Fatal intracranial or extracranial haemorrhage Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 INR 1.4 ‐ 2.8

1

2206

Risk Ratio (M‐H, Fixed, 95% CI)

1.4 [0.45, 4.40]

10.2 INR 2.0 ‐ 3.6

2

1203

Risk Ratio (M‐H, Fixed, 95% CI)

2.75 [0.94, 8.04]

10.3 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

17.37 [2.32, 130.11]

11 Intracranial haemorrhage, fatal or non‐fatal Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 INR 2.0 ‐ 3.6

2

1309

Risk Ratio (M‐H, Fixed, 95% CI)

1.77 [0.83, 3.74]

11.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

9.19 [2.80, 30.16]

12 Major extracranial haemorrhage Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 INR 2.0 ‐ 3.6

2

1309

Risk Ratio (M‐H, Fixed, 95% CI)

2.98 [1.56, 5.68]

12.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

8.85 [2.69, 29.11]
Figuras y tablas -
Comparison 3. Vitamin K antagonists versus aspirin only
Ir a la tabla de la revisión
Comparison 4. Vitamin K antagonists versus aspirin, including intracranial artery stenosis

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 The composite vascular death, non‐fatal stroke, non‐fatal myocardial infarction or major bleeding complication Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 INR 2.0 ‐ 3.6

3

1665

Risk Ratio (M‐H, Fixed, 95% CI)

1.10 [0.92, 1.32]

1.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.30 [1.58, 3.35]

2 All death Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 INR 1.4 ‐ 2.8

1

2206

Risk Ratio (M‐H, Fixed, 95% CI)

0.89 [0.60, 1.30]

2.2 INR 2.0 ‐ 3.6

5

2023

Risk Ratio (M‐H, Fixed, 95% CI)

1.47 [1.08, 2.00]

2.3 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.38 [1.31, 4.32]

3 Vascular death Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 INR 2.0 ‐ 3.6

4

1906

Risk Ratio (M‐H, Fixed, 95% CI)

1.43 [0.95, 2.16]

3.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.23 [1.10, 4.51]

4 Vascular death or non‐fatal stroke Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 INR 2.0 ‐ 3.6

4

1906

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.78, 1.18]

4.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

1.69 [1.08, 2.65]

5 Vascular death, non‐fatal stroke or non‐fatal myocardial infarction Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 INR 2.0 ‐ 3.6

3

1665

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.76, 1.13]

5.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

1.70 [1.12, 2.59]

6 Recurrent ischaemic stroke Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 INR 2.0 ‐ 3.6

4

1906

Risk Ratio (M‐H, Fixed, 95% CI)

0.83 [0.64, 1.06]

6.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.49, 2.13]

7 Recurrent ischaemic stroke or intracranial haemorrhage Show forest plot

6

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 INR 2.0 ‐ 3.6

5

2023

Risk Ratio (M‐H, Fixed, 95% CI)

0.90 [0.71, 1.13]

7.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.04 [1.21, 3.46]

8 Death or dependent at end of follow‐up Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

2.30 [1.37, 3.85]

9 Major bleeding complication Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 INR 1.4 ‐ 2.8

1

2206

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [0.79, 2.03]

9.2 INR 2.0 ‐ 3.6

5

2023

Risk Ratio (M‐H, Fixed, 95% CI)

2.07 [1.42, 3.03]

9.3 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

9.02 [3.91, 20.84]

10 Fatal intracranial or extracranial haemorrhage Show forest plot

6

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 INR 1.4 ‐ 2.8

1

2206

Risk Ratio (M‐H, Fixed, 95% CI)

1.4 [0.45, 4.40]

10.2 INR 2.0 ‐ 3.6

4

1800

Risk Ratio (M‐H, Fixed, 95% CI)

2.64 [1.04, 6.70]

10.3 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

17.37 [2.32, 130.11]

11 Intracranial haemorrhage, fatal or non‐fatal Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

11.1 INR 2.0 ‐ 3.6

4

1906

Risk Ratio (M‐H, Fixed, 95% CI)

1.83 [0.91, 3.68]

11.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

9.19 [2.80, 30.16]

12 Major extracranial haemorrhage Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

12.1 INR 2.0 ‐ 3.6

4

1906

Risk Ratio (M‐H, Fixed, 95% CI)

2.80 [1.69, 4.63]

12.2 INR 3.0 ‐ 4.5

1

1316

Risk Ratio (M‐H, Fixed, 95% CI)

8.85 [2.69, 29.11]
Figuras y tablas -
Comparison 4. Vitamin K antagonists versus aspirin, including intracranial artery stenosis
Ir a la tabla de la revisión